Moharem Heba A, Fetouh Fawzia Aboul, Darwish Hamed M, Ghaith Doaa, Elayashy Mohamed, Hussein Amr, Elsayed Riham, Khalil Mohammad M, Abdelaal Amr, ElMeteini Mahmoud, Mukhtar Ahmed
Department of Anesthesia, Surgical Intensive Care and Pain Management, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Department of Anesthesia, Surgical Intensive Care and Pain Management, Faculty of Medicine, Cairo University, 1 Alsaray st, Almanial, Cairo, Egypt.
BMC Anesthesiol. 2018 Apr 25;18(1):46. doi: 10.1186/s12871-018-0507-7.
Bacterial translocation (BT) has been proposed as a trigger for stimulation of the immune system with consequent hemodynamic alteration in patients with liver cirrhosis. However, no information is available regarding its hemodynamic and coagulation consequences during liver transplantation.
We screened 30 consecutive adult patients undergoing living-donor liver transplant for the presence of BT. Bacterial DNA, Anti factor Xa (aFXa), thromboelastometry, tumor necrosis factor-α TNF-α, and interleukin-17 (IL-17) values were measured in sera before induction of anesthesia. Systemic hemodynamic data were recorded throughout the procedures.
Bacterial DNA was detected in 10 patients (33%) (bactDNA(+)). Demographic, clinical, and hemodynamic data were similar in patients with presence or absence of bacterial DNA. BactDNA(+) patients showed significantly higher circulating values of TNF-α and IL-17, and had significantly higher clotting times and clot formation times as well as significantly lower alpha angle and maximal clot firmness than bactDNA(-) patients, P < 0.05. We found no statistically significant difference in aFXa between the groups, P = 0.4. Additionally, 4 patients in each group needed vasopressor agents, P = 0.2. And, the amount of transfused blood and blood products used were similar between both groups.
Bacterial translocation was found in one-third of patients at the time of transplantation and was largely associated with increased markers of inflammation along with decreased activity of coagulation factors.
Trial Registration Number: NCT03230214 . (Retrospective registered). Initial registration date was 20/7/2017.
细菌移位(BT)被认为是肝硬化患者免疫系统受刺激并随之发生血流动力学改变的触发因素。然而,关于其在肝移植期间的血流动力学和凝血后果尚无相关信息。
我们对30例连续接受活体肝移植的成年患者进行筛查,以检测是否存在细菌移位。在麻醉诱导前测定血清中的细菌DNA、抗Xa因子(aFXa)、血栓弹力图、肿瘤坏死因子-α(TNF-α)和白细胞介素-17(IL-17)值。在整个手术过程中记录全身血流动力学数据。
10例患者(33%)检测到细菌DNA(bactDNA(+))。有无细菌DNA的患者的人口统计学、临床和血流动力学数据相似。与bactDNA(-)患者相比,bactDNA(+)患者的TNF-α和IL-17循环值显著更高,凝血时间和血栓形成时间显著更长,α角和最大血栓硬度显著更低,P < 0.05。我们发现两组之间的aFXa无统计学显著差异,P = 0.4。此外,每组有4例患者需要血管升压药,P = 0.2。而且,两组使用的输血和血液制品量相似。
在移植时三分之一的患者中发现细菌移位,这在很大程度上与炎症标志物增加以及凝血因子活性降低有关。
试验注册号:NCT03230214。(回顾性注册)。初始注册日期为2017年7月20日。